Impact of treatment-related adverse events on efficacy of intralesional collagenase therapy for Peyronie's disease

Int J Impot Res. 2021 Jan;33(1):128-130. doi: 10.1038/s41443-020-0311-z. Epub 2020 May 26.

Authors

Dyvon T Walker¹, Robert H Shahinyan¹, Arash Amighi¹, Keith V Regets¹, Jesse N Mills¹, Sriram V Eleswarapu²

Affiliations

¹ Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
² Division of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. [email protected].

PMID: 32457499
DOI: 10.1038/s41443-020-0311-z

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Collagenases / administration & dosage*
Collagenases / therapeutic use
Ecchymosis / complications*
Humans
Injections, Intralesional
Male
Microbial Collagenase / administration & dosage*
Microbial Collagenase / therapeutic use
Middle Aged
Pain / complications*
Penile Induration / drug therapy*
Treatment Outcome

Substances

Collagenases
Microbial Collagenase